Boston Scientific (BSX) Tops Q4 EPS by 2c, FY EPS Guidance Trails Views at Mid-Point
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Boston Scientific (BSX) PT Raised to $45 at Credit Suisse
February 7, 2019 8:06 AM ESTCredit Suisse analyst Matt Miksic raised the price target on Boston Scientific (NYSE: BSX) to $45.00 (from $42.00) while maintaining a Outperform rating following the company's 4Q earnings report. Organic sales growth guidance for 2019 is 7-8.5%. EPS guidance for 2019 is $1.53-1.58, which includes dilution recent... More
Boston Scientific (BSX) PT Raised to $45 at Raymond James
February 7, 2019 7:25 AM ESTRaymond James analyst Jayson Bedford raised the price target on Boston Scientific (NYSE: BSX) to $45.00 (from $42.00) while maintaining a Strong Buy rating.
"... we ultimately believe this guidance will prove conservative (similar to prior years) and believe the dizzying (in a good way) amount of new products should drive 8%+ organic growth."
... MoreBoston Scientific (BSX) PT Raised to $44 at Jefferies
February 6, 2019 1:37 PM ESTJefferies analyst Raj Denhoy raised the price target on Boston Scientific (NYSE: BSX) to $44.00 (from $43.00) while maintaining a Buy rating.
... MoreBoston Scientific (BSX) PT Raised to $42 at Piper Jaffray
February 6, 2019 1:00 PM ESTPiper Jaffray analyst Matt O'Brien raised the price target on Boston Scientific (NYSE: BSX) to $42.00 (from $40.00) while maintaining a Overweight rating.
O'Brien said the strong revenue guidance trumps slightly below Street EPS outlook.
... More